CD4 and tuberculosis: The initial investments of expanding the program to include all patients with CD4+ cell counts of 201–350 cells/μl are likely to be even less than predicted by our model, because especially TB co-infected patients require more additional care and thus are more expensive than other HIV-infected patients.